Investigating the risk of heart and blood vessel problems in mild overactive thyroid disorder
Phase 4
Completed
- Conditions
- Sub clinical hyperthyroidismNutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN13184358
- Lead Sponsor
- Tan Tock Seng Hospital
- Brief Summary
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34823331/ (added 03/12/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1. Diagnosis of subclinical hyperthyroidism confirmed at least on two occasions (low serum TSH with normal FT4) and one normal FT3 levels within three months prior to the recruitment
2. Aged 21-85 years
3. Written informed consent
Exclusion Criteria
1. Sick euthyroid syndrome
2. Recent radioiodine therapy (within 1 year of screening visit)
3. Pregnant or breastfeeding patients
4. Acute medical illnesses such as infections and active cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evels of circulating endothelial progenitor cells (EPC), circulating endothelial cells (CEC), Hs CRP, ADMA, lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, Neutrophil lymphocyte ratio and monocyte lymphocyte ration in peripheral blood measured using an assay of blood sample at baseline and 6-months
- Secondary Outcome Measures
Name Time Method <br> At baseline and 6-months:<br> 1. Anthropometry<br> 1.1. Blood pressure (mmHg)<br> 1.2. Weight (kg)<br> 1.3. BMI (kg/m²)<br> 2. Thyroid hormones, and endothelial markers such as EPC, CEC, ADMA measured by blood test<br> 3. Cognitive assessments:<br> 3.1. Mini mental state examination (MMSE)<br> 3.2. Montreal cognitive assessment (MoCA)<br>